In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
BridgeBio Pharma Inc (NASDAQ: BBIO) closed the day trading at $42.78 down -0.93% from the previous closing price of $43.18. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 2.78 million shares were traded. BBIO stock price reached its highest trading level at $43.04 during the session, while it also had its lowest trading level at $41.8.
Ratios:
For a better understanding of BBIO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.54 and its Current Ratio is at 4.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on June 17, 2025, initiated with a Outperform rating and assigned the stock a target price of $49.
On March 31, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 27 ’25 when VIKING GLOBAL INVESTORS LP sold 3,500,000 shares for $44.00 per share. The transaction valued at 154,000,000 led to the insider holds 18,555,375 shares of the business.
KUMAR HALDEA REVOCABLETRUST U/ bought 120,000 shares of BBIO for $5,181,600 on Jul 01 ’25. On Jul 01 ’25, another insider, KUMAR HALDEA FAMILY IRREVOCABL, who serves as the Director of the company, bought 120,000 shares for $43.18 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 8123108352 and an Enterprise Value of 9526428672. For the stock, the TTM Price-to-Sale (P/S) ratio is 63.75. Its current Enterprise Value per Revenue stands at 74.767 whereas that against EBITDA is -14.376.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.15, which has changed by 0.7112 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $45.48, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 14.51%, while the 200-Day Moving Average is calculated to be 35.59%.
Shares Statistics:
Over the past 3-months, BBIO traded about 3.14M shares per day on average, while over the past 10 days, BBIO traded about 4134760 shares per day. A total of 189.83M shares are outstanding, with a floating share count of 160.76M. Insiders hold about 15.33% of the company’s shares, while institutions hold 85.60% stake in the company. Shares short for BBIO as of 1749772800 were 21119414 with a Short Ratio of 6.72, compared to 1747267200 on 22397501. Therefore, it implies a Short% of Shares Outstanding of 21119414 and a Short% of Float of 18.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
